asco 2021 lung recap: impower010: atezolizumab after chemo in non-small cell lung cancer
Published 2 years ago • 615 plays • Length 14:00Download video MP4
Download video MP3
Similar videos
-
5:27
asco 2021 lung recap: lurbinectedin in small cell lung cancer and the failed atlantis trial
-
8:13
asco 2021 lung recap: fda analysis of immunotherapy with or without chemo in adv nsclc and low pdl-1
-
6:38
asco 2021 lung recap: poseidon trial: durvalumab /- tremelimumab vs. chemo alone
-
6:10
asco 2021 lung recap: circulatory tumor dna
-
1:58
impower 010: adjuvant atezolizumab in nsclc - onctalk lung 2023
-
11:30
asco 2021 lung recap: surgical outcomes & checkmate 816: nivolumab in early stage nsclc
-
8:08
asco 2021 lung recap: mylung consortium: overall biomarker testing
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
4:45
the skyscraper trial: treatments for extensive stage small cell lung cancer - asco lung review 2022
-
5:26
asco 2021 lung recap: codebreak 100: sotorasib in kras g12c mutation
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
4:42
asco lung cancer roundtable - new combinations chemo immunotherapy for extensive stage sclc
-
14:43
the need for molecular testing in lung cancer - asco lung review 2022
-
9:28
asco 2021 lung: amivantamab lazertinib in egfr, patritumab deruxtecan in egfr acquired resistance
-
11:58
asco lung cancer roundtable - mesothelioma updates
-
6:02
choices among immunotherapeutics may be the future of lung cancer care
-
2:11
asco lung cancer highlights, pt 13: immune checkpoint inhibitor mpdl3280a in advanced nsclc
-
5:45
asco highlights, pt 10: after resistance to crizotinib in alk-positive advanced nsclc